Search

Displaying results 2221 - 2230 of 10000 in total
  1. Target

    Short transient receptor potential channel 5

    go.drugbank.com/bio_entities/BE0021113
    TargetHumans

    Forms a receptor-activated non-selective calcium permeant cation channel (PubMed:16284075, PubMed:38959890, PubMed:37137991).

    Polypeptides: Short transient receptor potential channel 5Synonyms: Transient receptor protein 5
  2. Target

    Taste receptor type 2 member 14

    go.drugbank.com/bio_entities/BE0023216
    TargetHumans

    Gustducin-linked G protein-coupled receptor that plays a role in the perception of bitterness (PubMed:38600377, PubMed:38776963). … The activity of this receptor stimulates GNAT3, activating the gustducin G protein pathway (PubMed:38600377, PubMed:38776963).

    Polypeptides: Taste receptor type 2 member 14Synonyms: Taste receptor family B member 1
  3. Drug

    Difenoxin

    go.drugbank.com/drugs/DB01501
    ApprovedIllicit

    Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). … However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids.

  4. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. … [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  5. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    It is currently being tested as a radiation sensitizer. … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

  6. Drug

    Magnesium citrate

    go.drugbank.com/drugs/DB11110
    ApprovedInvestigational

    [L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.

  7. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder.[A31634] It is a piperazinyl-triazole derivative.[T83]

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  8. Drug

    Balsalazide

    go.drugbank.com/drugs/DB01014
    Approved

    Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. … The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.

  9. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma.

  10. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]